Transcarent has announced the successful completion of its merger with Accolade, a leading company in health advocacy, expert medical opinion, and virtual primary care. This merger forms a combined organization that now serves over 20 million members and more than 1,700 employer and health plan clients, positioning itself as the single destination for health and care. With this integration, Transcarent is enhancing its ability to deliver an unmatched health and care experience, offering greater choice, quality, and affordability to health consumers, self-insured employers, and health plans.

The new organization will combine Transcarent’s AI-powered WayFinding system and its comprehensive Care Experiences—including Cancer Care, Surgery Care, and Weight Health—with Accolade’s established strength in health advocacy, medical opinion, and virtual care. Together, they provide a broad range of services designed to simplify access to healthcare, improve outcomes, and lower costs. CEO Glen Tullman emphasized that this merger is a critical step toward making high-quality, affordable care easier to access, supported by tools like WayFinding, which offers personalized answers and immediate access to care options, whether that’s virtual appointments, expert consultations, or care for complex health needs.

By merging their advanced technologies and services, Transcarent and Accolade aim to deliver the most comprehensive and personalized health and care experience available. Their shared investment in AI has led to the development of industry-leading tools such as WayFinding, which helps people understand and navigate their benefits while providing immediate access to care providers, and Accolade’s True Health Actions, which generate personalized care plans using data from health records, employers, and health plans. These plans help guide member outreach, care suggestions, and coordination between members and Care Advocates.

Engineers from both companies have pioneered generative AI tools that enhance the productivity of clinicians by reducing administrative burdens such as billing and prescriptions, allowing them to focus more on patient care. This focus on streamlined, patient-centric care ensures that health consumers receive the support they need, whenever and however they choose—whether that means getting care within 60 seconds, speaking to a Care Assistant, or scheduling ongoing treatment for chronic or complex conditions.

Transcarent’s platform is built to support health journeys from simple needs to serious conditions, providing personalized guidance and clear Health Action Plans aimed at delivering better outcomes. The company remains committed to a quality-first approach, offering access to trusted partners, expert physicians through services like 2nd.MD, and preventing unnecessary treatments by ensuring quality consultations are available early in the care process.

Additionally, the combined organization offers more choice than ever before through the integration of Accolade’s Trusted Partner Ecosystem and Transcarent’s provider relationships, all housed within a unified Experience Store. Employers and health plans can now access a wide range of point solutions across mental health, diabetes, fertility, musculoskeletal care, and more—all through a secure platform with single sign-on integration. According to Snezana Mahon, President of Transcarent, this merger creates the largest Experience Store of its kind, offering personalized, easily accessible solutions that enhance care quality, increase engagement, and reduce costs, far surpassing traditional health navigation.

The transaction, initially announced on January 8, was completed within three months. Under the agreement, Accolade shareholders received $7.03 per share in cash. The acquisition, valued at approximately $621 million, was financed by General Catalyst, Glen Tullman’s 62 Ventures, and other investors, with additional support from J.P. Morgan. With all regulatory and shareholder approvals secured, Accolade is now a part of the privately held Transcarent, and its stock is no longer publicly traded on Nasdaq.